485 related articles for article (PubMed ID: 25915617)
1. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.
Grbesa I; Pajares MJ; Martínez-Terroba E; Agorreta J; Mikecin AM; Larráyoz M; Idoate MA; Gall-Troselj K; Pio R; Montuenga LM
PLoS One; 2015; 10(4):e0124670. PubMed ID: 25915617
[TBL] [Abstract][Full Text] [Related]
2. Regulation of SIRT2 levels for human non-small cell lung cancer therapy.
Li Z; Xie QR; Chen Z; Lu S; Xia W
Lung Cancer; 2013 Oct; 82(1):9-15. PubMed ID: 23915912
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.
Ma L; Maruwge W; Strambi A; D'Arcy P; Pellegrini P; Kis L; de Milito A; Lain S; Brodin B
Cell Death Dis; 2014 Oct; 5(10):e1483. PubMed ID: 25341037
[TBL] [Abstract][Full Text] [Related]
4. Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells.
Singh S; Kumar PU; Thakur S; Kiran S; Sen B; Sharma S; Rao VV; Poongothai AR; Ramakrishna G
Tumour Biol; 2015 Aug; 36(8):6159-71. PubMed ID: 25794641
[TBL] [Abstract][Full Text] [Related]
5. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
[TBL] [Abstract][Full Text] [Related]
6. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
Hoffmann G; Breitenbücher F; Schuler M; Ehrenhofer-Murray AE
J Biol Chem; 2014 Feb; 289(8):5208-16. PubMed ID: 24379401
[TBL] [Abstract][Full Text] [Related]
7. SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Xu W; Jiang K; Shen M; Qian Y; Peng Y
Biol Chem; 2015 Aug; 396(8):929-36. PubMed ID: 25719312
[TBL] [Abstract][Full Text] [Related]
8. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Li Z; Huang J; Yuan H; Chen Z; Luo Q; Lu S
Oncotarget; 2016 Apr; 7(14):18927-39. PubMed ID: 26942878
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer.
Gharabaghi MA
Clin Respir J; 2018 Feb; 12(2):633-638. PubMed ID: 27768839
[TBL] [Abstract][Full Text] [Related]
10. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner.
McCarthy AR; Sachweh MC; Higgins M; Campbell J; Drummond CJ; van Leeuwen IM; Pirrie L; Ladds MJ; Westwood NJ; Laín S
Mol Cancer Ther; 2013 Apr; 12(4):352-60. PubMed ID: 23322738
[TBL] [Abstract][Full Text] [Related]
11. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
Nihal M; Ahmad N; Wood GS
Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).
Bhalla S; Gordon LI
Cancer Biol Ther; 2016; 17(3):300-9. PubMed ID: 26794150
[TBL] [Abstract][Full Text] [Related]
13. miR‑150 promotes the proliferation and migration of non‑small cell lung cancer cells by regulating the SIRT2/JMJD2A signaling pathway.
Jiang K; Shen M; Chen Y; Xu W
Oncol Rep; 2018 Aug; 40(2):943-951. PubMed ID: 29901178
[TBL] [Abstract][Full Text] [Related]
14. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
Wilking MJ; Singh C; Nihal M; Zhong W; Ahmad N
Arch Biochem Biophys; 2014 Dec; 563():94-100. PubMed ID: 24751483
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SIRT1/2 upregulates HSPA5 acetylation and induces pro-survival autophagy via ATF4-DDIT4-mTORC1 axis in human lung cancer cells.
Mu N; Lei Y; Wang Y; Wang Y; Duan Q; Ma G; Liu X; Su L
Apoptosis; 2019 Oct; 24(9-10):798-811. PubMed ID: 31321634
[TBL] [Abstract][Full Text] [Related]
16. SIRT2: tumour suppressor or tumour promoter in operable breast cancer?
McGlynn LM; Zino S; MacDonald AI; Curle J; Reilly JE; Mohammed ZM; McMillan DC; Mallon E; Payne AP; Edwards J; Shiels PG
Eur J Cancer; 2014 Jan; 50(2):290-301. PubMed ID: 24183459
[TBL] [Abstract][Full Text] [Related]
17. SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.
Luo J; Bao YC; Ji XX; Chen B; Deng QF; Zhou SW
Biochem Biophys Res Commun; 2017 Feb; 483(2):880-884. PubMed ID: 28073696
[TBL] [Abstract][Full Text] [Related]
18. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line.
Marx C; Marx-Blümel L; Lindig N; Thierbach R; Hoelzer D; Becker S; Wittig S; Lehmann R; Slevogt H; Heinzel T; Wang ZQ; Beck JF; Sonnemann J
Invest New Drugs; 2018 Jun; 36(3):396-406. PubMed ID: 29150734
[TBL] [Abstract][Full Text] [Related]
19. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.
Zhang T; Rong N; Chen J; Zou C; Jing H; Zhu X; Zhang W
PLoS One; 2013; 8(11):e79162. PubMed ID: 24223900
[TBL] [Abstract][Full Text] [Related]
20. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.
Lara E; Mai A; Calvanese V; Altucci L; Lopez-Nieva P; Martinez-Chantar ML; Varela-Rey M; Rotili D; Nebbioso A; Ropero S; Montoya G; Oyarzabal J; Velasco S; Serrano M; Witt M; Villar-Garea A; Imhof A; Mato JM; Esteller M; Fraga MF
Oncogene; 2009 Feb; 28(6):781-91. PubMed ID: 19060927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
